title: Next generation immunotherapeutics--honing the magic bullet.
abstract: Most therapeutic antibodies in the clinic today are based on fully humanised immunoglobulins. They have proven to be outstandingly effective, especially for the treatment of cancer, autoimmune and inflammatory diseases where the target is a single, well-defined and accessible molecule. Many diseases however are complex, involving multiple mediators or signalling pathways that could be targeted simultaneously to maximise clinical benefit. There is also a wealth of validated intracellular and CNS-based targets which are currently inaccessible to monoclonal antibody therapy. A spectrum of next generation immunotherapeutics is in development to address these issues and a number of them have also entered clinical trials.
authors.affiliation: Domantis Ltd, 315 Science Park, Cambridge CB4 0WG, UK. Carrie.Enever@Domantis.com
authors.forename: Carrie
authors.initials: C
authors.lastname: Enever
authors.forename: Thil
authors.initials: T
authors.lastname: Batuwangala
authors.forename: Chris
authors.initials: C
authors.lastname: Plummer
authors.forename: Armin
authors.initials: A
authors.lastname: Sepp
mesh_terms: D000918:Antibody Specificity; D006801:Humans; D007128:Immunoglobulin Fragments / Q000627:therapeutic use*; D007167:Immunotherapy
chemical_list: D007128:Immunoglobulin Fragments